Cited by 363Retinoids in leukemia and cellular processesAcute Myeloid Leukemia ResearchAcute Lymphoblastic Leukemia research

The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.

Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors

Open access

Montesinos, Pau, Bergua, Juan M., Vellenga, Edo, Rayón, Chelo, Parody, Ricardo, de la Serna, Javier, León, Angel, Esteve, Jordi, Milone, Gustavo, Debén, Guillermo, Rivas, Concha, González, Marcos, Tormo, Mar, Díaz-Mediavilla, Joaquín, González, Jose D., Negri, Silvia, Amutio, Elena, Brunet, Salut, Lowenberg, Bob, Sanz, Miguel A.·2009·Blood

DOI 10.1182/blood-2008-07-168617

Open this paper in CoChat — free account Open PDF

Abstract

Differentiation syndrome (DS) can be a life-threatening complication in patients with acute promyelocytic leukemia (APL) undergoing induction therapy with all-trans retinoic acid (ATRA). Detailed knowledge about DS has remained limited. We present an analysis of the incidence, characteristics, prognostic factors, and outcome of 739 APL patients treated with ATRA plus idarubicin in 2 consecutive trials (Programa Español de Tratamientos en Hematología [PETHEMA] LPA96 and LPA99). Overall, 183 patients (24.8%) experienced DS, 93 with a severe form (12.6%) and 90 with a moderate form (12.2%). Severe but not moderate DS was associated with an increase in mortality. A bimodal incidence of DS was observed, with peaks occurring in the first and third weeks after the start of ATRA therapy. A multivariate analysis indicated that a WBC count greater than 5 × 109/L and an abnormal serum creatinine level correlated with an increased risk of developing severe DS. Patients receiving systematic prednisone prophylaxis (LPA99 trial) in contrast to those receiving selective prophylaxis with dexamethasone (LPA96 trial) had a lower incidence of severe DS. Patients developing severe DS showed a reduced 7-year relapse-free survival in the LPA96 trial (60% vs 85%, P = .003), but this difference was not apparent in the LPA99 trial (86% vs 88%).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1182/blood-2008-07-168617

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Proposals for the Classification of the Acute Leukaemias F rench ‐A merican ‐B ritish (FAB) C o‐operative G roup
Bennett, J. M., Catovsky, D., Mt, D., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1976) · British Journal of Haematology · doi:10.1111/j.1365-2141.1976.tb03563.x · Cited by 5,595
BMDP Statistical Software 1981.
Bubolz, T. A., & Dixon, W. J. (1984) · Journal of the American Statistical Association · doi:10.2307/2288308 · Cited by 5,231
Statistical Methods for Survival Data Analysis.
Lachenbruch, P. A., & Lee, E. T. (1993) · Journal of the American Statistical Association · doi:10.2307/2290742 · Cited by 2,851
Analysis of Binary Data
Cox, D. R. (2008) · Springer eBooks · doi:10.1007/978-0-387-32833-1_5 · Cited by 2,687
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
Cheson, B. D., Bennett, J. M., Kopecky, K. J., Büchner, T., Willman, C. L., Estey, E. H., Schiffer, C. A., Döhner, H., Tallman, M. S., Lister, T. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.036 · Cited by 2,686
Self-citation
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
Creutzig, U., & Kaspers, G. J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.116 · Cited by 2,137

Show all 42 references

Research works printed but not linked: 1

Dixon, 1990, BMDP Statistical Software

Sorted by citations

Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
Lo-Coco, F., Avvisati, G., Vignetti, M., Thiede, C., Orlando, S. M., Iacobelli, S., Ferrara, F., Fazi, P., Cicconi, L., Di Bona, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300874 · Cited by 1,611
Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial
Platzbecker, U., Avvisati, G., Cicconi, L., Thiede, C., Paoloni, F. P., Vignetti, M., Ferrara, F., Divona, M., Albano, F., Efficace, F., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1982 · Cited by 388
Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry
Lehmann, S., Landtblom, A. R., Carlsson, L., Antunović, P., Deneberg, S., Möllgård, L., Derolf, Å. R., Stockelberg, D., Tidefelt, U., Wåhlin, A., et al. (2011) · Leukemia · doi:10.1038/leu.2011.78 · Cited by 343
Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome
Sanz, M. Á., Montesinos, P., Rayón, C., Holowiecka, A., de la Serna, J., Milone, G., de Lisa, E., Brunet, S., Rubio, V., Ribera, J., et al. (2010) · Blood · doi:10.1182/blood-2010-01-266007 · Cited by 328
Self-citation
How I treat acute promyelocytic leukemia
Tallman, M. S., & Altman, J. K. (2009) · Blood · doi:10.1182/blood-2009-07-216457 · Cited by 284
Acute promyelocytic leukemia current treatment algorithms
Yilmaz, M. E., Kantarjian, H. M., & Ravandi, F. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00514-3 · Cited by 241
Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics
Golub, D., Iyengar, N. S., Dogra, S., Wong, T., Bready, D., Tang, K., Modrek, A. S., & Placantonakis, D. G. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00417 · Cited by 234
How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia
Sanz, M. Á., & Montesinos, P. (2014) · Blood · doi:10.1182/blood-2013-10-512640 · Cited by 181
Self-citation
Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic
Shah, F., Logsdon, D. P., Messmann, R. A., Fehrenbacher, J. C., Fishel, M. L., & Kelley, M. R. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0023-0 · Cited by 155
Gilteritinib: potent targeting of FLT3 mutations in AML
Levis, M. J., & Perl, A. E. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000174 · Cited by 151
Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial
Zhu, H., Wu, D., Du, X., Zhang, X., Liu, L., Ma, J., Shao, Z., Ren, H., Hu, J., Xu, K., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30295-x · Cited by 145
Differentiation syndrome in acute promyelocytic leukaemia
Stahl, M. F., & Tallman, M. S. (2019) · British Journal of Haematology · doi:10.1111/bjh.16151 · Cited by 152
Current management of newly diagnosed acute promyelocytic leukemia
Cicconi, L., & Lo‐Coco, F. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw171 · Cited by 145
Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens
Montesinos, P., Rayón, C., Vellenga, E., Brunet, S., González, J., González, M., Hołowiecka, A., Esteve, J., Bergua, J., González, J. D., et al. (2010) · Blood · doi:10.1182/blood-2010-04-277434 · Cited by 141
Self-citation
FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation
Norsworthy, K. J., Luo, L., Hsu, V., Gudi, R., Dorff, S. E., Przepiorka, D., Deisseroth, A., Shen, Y. L., Sheth, C. M., Charlab, R., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3749 · Cited by 141
Advances and challenges in retinoid delivery systems in regenerative and therapeutic medicine
Ferreira, R., Napoli, J., Enver, T., Bernardino, L., & Ferreira, L. (2020) · Nature Communications · doi:10.1038/s41467-020-18042-2 · Cited by 138
CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells
Gong, K., Xie, J., Yi, H., & Li, W. (2012) · Biochemical Journal · doi:10.1042/bj20111685 · Cited by 131
Bleeding and thrombosis in acute promyelocytic leukemia
Choudhry, A., & DeLoughery, T. G. (2012) · American Journal of Hematology · doi:10.1002/ajh.23158 · Cited by 128
UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6)
de Médecine, F., Curie, M., Générale, M., & Pelizzari, M. (2011) · Cited by 123
High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG
Lengfelder, E., Haferlach, C., Saußele, S., Haferlach, T., Schultheis, B. S., Schnittger, S., Ludwig, W., Staib, P., Aul, C., Grüneisen, A., et al. (2009) · Leukemia · doi:10.1038/leu.2009.183 · Cited by 121
All-trans retinoic acid stealth liposomes prevent the relapse of breast cancer arising from the cancer stem cells
Li, R.-J., Ying, X., Zhang, Y., Ju, R.-J., Wang, X.-X., Yao, H.-J., Men, Y., Tian, W., Yu, Y., Zhang, L., et al. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.10.019 · Cited by 119
Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome
Luesink, M., Pennings, J. L. A., Wissink, W. M., Linssen, P. C. M., Muus, P., Pfundt, R., de Witte, T. J. M., van der Reijden, B. A., & Jansen, J. H. (2009) · Blood · doi:10.1182/blood-2009-02-204834 · Cited by 117
Sepsis and Cancer: An Interplay of Friends and Foes
Mirouse, A., Vigneron, C., Llitjos, J., Chiche, J., Mira, J. P., Mokart, D., Azoulay, É., & Pène, F. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202004-1116tr · Cited by 115
Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis
Norsworthy, K. J., Mulkey, F. A., Scott, E., Ward, A. F., Przepiorka, D., Charlab, R., Dorff, S. E., Deisseroth, A., Kazandjian, D. G., Sridhara, R., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0834 · Cited by 115
Understanding and Managing Sepsis in Patients With Cancer in the Era of Antimicrobial Resistance
Gudiol, C., Albasanz‐Puig, A., Cuervo, G., & Carratalà, J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.636547 · Cited by 119
Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial
Stein, E. M., Fathi, A. T., Dinardo, C. D., Pollyea, D. A., Roboz, G. J., Collins, R. H., Sekeres, M. A., Stone, R. M., Attar, E. C., Frattini, M. G., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30284-4 · Cited by 109
THE DIFFERENTIATION SYNDROME IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA: EXPERIENCE OF THE PETHEMA GROUP AND REVIEW OF THE LITERATURE.
Montesinos, P., & Sanz, M. Á. (2011) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2011.059 · Cited by 105
Self-citation
Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system
Babiker, H. M., McBride, A., Newton, M., Boehmer, L., Drucker, A., Gowan, M., Cassagnol, M., Camenisch, T. D., Anwer, F., & Hollands, J. M. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.03.014 · Cited by 104
Acute promyelocytic leukemia (APL): remaining challenges towards a cure for all
Stahl, M. F., & Tallman, M. S. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1613540 · Cited by 101
How to manage acute promyelocytic leukemia
Mi, J.-Q., Li, J., Shen, Z.-X., Chen, S.-J., & Chen, Z. (2012) · Leukemia · doi:10.1038/leu.2012.57 · Cited by 97
Management of patients with acute promyelocytic leukemia
Käyser, S., Schlenk, R. F., & Platzbecker, U. (2018) · Leukemia · doi:10.1038/s41375-018-0139-4 · Cited by 95
Proteomic cell surface phenotyping of differentiating acute myeloid leukemia cells
Hofmann, A., Gerrits, B., Schmidt, A., Bock, T., Bausch‐Fluck, D., Aebersold, R. H., & Wollscheid, B. (2010) · Blood · doi:10.1182/blood-2010-02-271270 · Cited by 90
Soluble RARRES1 induces podocyte apoptosis to promote glomerular disease progression
Chen, A., Feng, Y., Lai, H., Ju, W., Li, Z., Yu, L., Wang, A. A., Hong, Q., Zhong, F., Wei, C., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci140155 · Cited by 90
Combined Low Doses of PPARγ and RXR Ligands Trigger an Intrinsic Apoptotic Pathway in Human Breast Cancer Cells
Bonofiglio, D., Cione, E., Qi, H., Pingitore, A., Perri, M., Catalano, S., Vizza, D., Panno, M. L., Genchi, G., Fuqua, S. A. W., et al. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.081078 · Cited by 85
Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL
Testi, A. M., Pession, A., Diverio, D., Grimwade, D. J., Gibson, B. E. S., de Azevedo, A. C., Moran, L. E., Leverger, G., Elitzur, S., Hasle, H., et al. (2018) · Blood · doi:10.1182/blood-2018-03-836528 · Cited by 82
A novel NUP98/RARG gene fusion in acute myeloid leukemia resembling acute promyelocytic leukemia
Such, E., Cervera, J., Valencia, A., Barragán, E., Ibáñez, M., Luna, I., Fuster, Ó., Perez-Sirvent, M. L., Senent, L., Sempere, A., et al. (2010) · Blood · doi:10.1182/blood-2010-06-291658 · Cited by 79
Self-citation
Open issues on bleeding and thrombosis in acute promyelocytic leukemia
Sanz, M. Á., & Montesinos, P. (2010) · Thrombosis Research · doi:10.1016/s0049-3848(10)70013-x · Cited by 79
Self-citation
Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients
Testa, U., & Lo‐Coco, F. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2622-1 · Cited by 82
Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives
McCulloch, D., Brown, C. M., & Iland, H. J. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s100513 · Cited by 76
Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients
Rahmé, R., Thomas, X., Récher, C., Vey, N., Delaunay, J., Deconinck, É., Hirsch, P., Bordessoule, D., Micol, J.-B., Stamatoullas, A., et al. (2014) · Leukemia · doi:10.1038/leu.2014.240 · Cited by 75
Differentiation therapy of myeloid leukemia: four decades of development
Madan, V., & Koeffler, H. P. (2020) · Haematologica · doi:10.3324/haematol.2020.262121 · Cited by 72
How I treat hematologic emergencies in adults with acute leukemia
Zuckerman, T., Ganzel, C., Tallman, M. S., & Rowe, J. M. (2012) · Blood · doi:10.1182/blood-2012-04-424440 · Cited by 68
Acute Promyelocytic Leukemia: A History over 60 Years—From the Most Malignant to the most Curable Form of Acute Leukemia
Thomas, X. (2019) · Oncology and Therapy · doi:10.1007/s40487-018-0091-5 · Cited by 68
Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy
Barragán, E., Montesinos, P., Camós, M., González, M., Calasanz, M. J., Román‐Gómez, J., Gómez‐Casares, M. T., Ayala, R. M., Lopez, J., Fuster, Ó., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.044933 · Cited by 64
Self-citation
Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols
Breccia, M., Mazzarella, L., Bagnardi, V., Disalvatore, D., Loglisci, G., Cimino, G. G., Testi, A. M., Avvisati, G., Petti, M. C., Minotti, C., et al. (2011) · Blood · doi:10.1182/blood-2011-07-369595 · Cited by 65
Multicenter randomized trial of arsenic trioxide and Realgar‐ Indigo naturalis formula in pediatric patients with acute promyelocytic leukemia: Interim results of the SCCLG‐APL clinical study
Yang, M., Wan, W., Luo, J., Zheng, M., Huang, K., Yang, L., Mai, H., Li, J., Chen, H. Q., Sun, X., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25271 · Cited by 64
Thrombosis in acute promyelocytic leukemia
Rashidi, A., Silverberg, M. L., Conkling, P., & Fisher, S. I. (2012) · Thrombosis Research · doi:10.1016/j.thromres.2012.11.024 · Cited by 64
The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia
Dalle, I. A., & Dinardo, C. D. (2018) · Therapeutic Advances in Hematology · doi:10.1177/2040620718777467 · Cited by 60
IDH Inhibitors in AML—Promise and Pitfalls
McMurry, H. S., Fletcher, L. B., & Traer, E. A. (2021) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-021-00619-3 · Cited by 56
Acute promyelocytic leukemia: preventing early complications and late toxicities
Abedin, S. M., & Altman, J. K. (2016) · Hematology · doi:10.1182/asheducation-2016.1.10 · Cited by 56
Advances in the management of coagulopathy in acute promyelocytic leukemia
Sanz, M. Á., & Montesinos, P. (2020) · Thrombosis Research · doi:10.1016/s0049-3848(20)30399-6 · Cited by 53
Self-citation
Characteristics and predictors of early hospital deaths in newly diagnosed APL: a 13-year population-wide study
Gill, H., Yung, Y., Chu, H.-T., Au, W., Yip, P.-K., Lee, E., Yim, R., Lee, P., Cheuk, D. K., Ha, S., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004789 · Cited by 51
Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four CALGB (alliance) clinical trials
Castillo, J. J., Mulkey, F. A., Geyer, S. M., Kolitz, J. E., Blum, W. G., Powell, B. L., George, S. L., Larson, R. A., & Stone, R. M. (2015) · American Journal of Hematology · doi:10.1002/ajh.24230 · Cited by 52
Advances in understanding the pulmonary infiltration in acute promyelocytic leukaemia
Luesink, M., & Jansen, J. H. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08325.x · Cited by 51
Arsenic Combined With All-Trans Retinoic Acid for Pediatric Acute Promyelocytic Leukemia: Report From the CCLG-APL2016 Protocol Study
Zheng, H., Jiang, H., Hu, S., Liao, N., Shen, D., Tian, X., Hao, G., Jin, R., Li, J., Fang, Y., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03096 · Cited by 48
Differentiation syndrome in patients with acute promyelocytic leukemia
Rogers, J. E., & Yang, D. (2011) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155211399163 · Cited by 49
DIFFERENTIATION SYNDROME IN PROMYELOCYTIC LEUKEMIA : CLINICAL PRESENTATION, PATHOGENESIS AND TREATMENT
Rego, E. M., & Santis, G. C. D. (2011) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2011.048 · Cited by 49
Predictors of early hemorrhage in acute promyelocytic leukemia
Naymagon, L., Moshier, E. L., Tremblay, D. A., & Mascarenhas, J. O. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1581187 · Cited by 46
Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia
Fruchtman, H., Avigan, Z. M., Waksal, J. A., Brennan, N., & Mascarenhas, J. O. (2024) · Leukemia · doi:10.1038/s41375-024-02246-2 · Cited by 59
Oral arsenic and all-trans retinoic acid for high-risk acute promyelocytic leukemia
Zhu, H., Liu, Y., Jia, J., Qin, Y., Zhao, X.-S., & Lai, Y. (2018) · Blood · doi:10.1182/blood-2018-02-834051 · Cited by 47
Differentiation syndrome with lower‐intensity treatments for acute myeloid leukemia
Fathi, A. T., Stein, E. M., Dinardo, C. D., Levis, M. J., Montesinos, P., & de Botton, S. (2021) · American Journal of Hematology · doi:10.1002/ajh.26142 · Cited by 46
Self-citation
How I treat acute myeloid leukemia with differentiation therapy
Issa, G. C., Stein, E. M., & Dinardo, C. D. (2024) · Blood · doi:10.1182/blood.2024024008 · Cited by 46
FNDC3B is another novel partner fused to RARA in the t(3;17)(q26;q21) variant of acute promyelocytic leukemia
Cheng, C. K., Wang, A. Z., Wong, T. H. Y., Wan, T. S. K., Cheung, J. S., Raghupathy, R., Chan, N. P. H., & Ng, M. H. L. (2017) · Blood · doi:10.1182/blood-2017-02-767707 · Cited by 44
All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies
Groups, O. B. O. T. I.-A. A. P. A. H., Sanz, M. Á., Montesinos, P., Kim, H. T., Ruiz-Argüelles, G. J., Undurraga, M. S., Uriarte, M., Martínez, L., Jácomo, R. H., Gutiérrez‐Aguirre, C. H., et al. (2015) · Annals of Hematology · doi:10.1007/s00277-015-2393-0 · Cited by 43
Self-citation
Enasidenib for the treatment of acute myeloid leukemia
Dugan, J. P., & Pollyea, D. A. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1477585 · Cited by 43
Inhibition of the redox function of APE1/Ref-1 in myeloid leukemia cell lines results in a hypersensitive response to retinoic acid-induced differentiation and apoptosis
Fishel, M. L., Colvin, E. S., Luo, M., Kelley, M. R., & Robertson, K. A. (2010) · Experimental Hematology · doi:10.1016/j.exphem.2010.08.011 · Cited by 43
Novel Retinoic Acid Receptor Alpha Agonists for Treatment of Kidney Disease
Zhong, Y., Wu, Y., Liu, R., Li, Z., Chen, Y., Evans, T., Chuang, P. Y., Das, B. C., & He, C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027945 · Cited by 42
Enasidenib and ivosidenib in AML
Martelli, M. P., Martino, G., Cardinali, V., Falini, B., Martinelli, G., & Cerchione, C. (2020) · Minerva Medica · doi:10.23736/s0026-4806.20.07024-x · Cited by 42
Management of fever and neutropenia in the adult patient with acute myeloid leukemia
Peseski, A. M., McClean, M., Green, S. D., Beeler, C., & Koenig, H. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1820863 · Cited by 39
Enhanced growth inhibition of metastatic lung tumors by intravenous injection of ATRA-cationic liposome/IL-12 pDNA complexes in mice
Charoensit, P., Kawakami, S., Higuchi, Y., Yamashita, F., & Hashida, M. (2010) · Cancer Gene Therapy · doi:10.1038/cgt.2010.12 · Cited by 40
[Chinese guidelines for diagnosis and treatment of acute promyelocytic leukemia (2018)].
(2018) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2018.03.002 · Cited by 40
Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML
de Botton, S., Cluzeau, T., Vigil, C. E., Cook, R. J., Rousselot, P. H., Rizzieri, D. A., Liesveld, J. L., Fenaux, P., Braun, T., Banos, A., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022008806 · Cited by 38
High body mass index is an independent predictor of differentiation syndrome in patients with acute promyelocytic leukemia
Jeddi, R., Ghédira, H., Mnif, S., Gouider, E., Fenaux, P., & Meddeb, B. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.09.017 · Cited by 37
Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group
Tallman, M. S., Kim, H. T., Montesinos, P., Appelbaum, F. R., de la Serna, J., Bennett, J. M., Debén, G., Bloomfield, C. D., González, J. D., Feusner, J. H., et al. (2010) · Blood · doi:10.1182/blood-2010-06-288613 · Cited by 37
Self-citation
Incidence of Differentiation Syndrome Associated with Treatment Regimens in Acute Myeloid Leukemia: A Systematic Review of the Literature
Gasparovic, L., Weiler, S., Higi, L., & Burden, A. M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103342 · Cited by 37
Atypical Rearrangements in APL-Like Acute Myeloid Leukemias: Molecular Characterization and Prognosis
Guarnera, L., Ottone, T., Fabiani, E., Divona, M., Savi, A., Travaglini, S., Falconi, G., Panetta, P., Rapanotti, M. C., & Voso, M. T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.871590 · Cited by 40
Differentiation Syndrome in Acute Leukemia: APL and Beyond
Woods, A. C., & Norsworthy, K. J. (2023) · Cancers · doi:10.3390/cancers15194767 · Cited by 35
IDH1-mutated relapsed or refractory AML: current challenges and future prospects
Megías‐Vericat, J. E., Ballesta‐López, O., Barragán, E., & Montesinos, P. (2019) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s177913 · Cited by 35
Self-citation
Hemorrhage in acute promyelocytic leukemia: Can it be predicted and prevented?
Naymagon, L., & Mascarenhas, J. O. (2020) · Leukemia Research · doi:10.1016/j.leukres.2020.106356 · Cited by 36
Synergistic targeted therapy for acute promyelocytic leukaemia: a model of translational research in human cancer
Mi, J.-Q., Chen, S., Zhou, G., Yan, X., & Chen, Z. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12376 · Cited by 33
Clinical characteristics, outcome and early induction deaths in patients with acute promyelocytic leukaemia: a five-year experience at a tertiary care centre
Karim, F., Shaikh, U., Adil, S., & Khurshid, M. S. (2014) · Singapore Medical Journal · doi:10.11622/smedj.2014105 · Cited by 34
New Therapeutic Strategies for Adult Acute Myeloid Leukemia
Ishii, H., & Yano, S. (2022) · Cancers · doi:10.3390/cancers14112806 · Cited by 33
Predictors of early death, serious hemorrhage, and differentiation syndrome in Japanese patients with acute promyelocytic leukemia
Minamiguchi, H., Fujita, H., Atsuta, Y., Asou, N., Sakura, T., Ueda, Y., Sawa, M., Dobashi, N., Taniguchi, Y., Suzuki, R., et al. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04245-6 · Cited by 33
Kidney diseases associated with haematological cancers
Ganguli, A., Sawinski, D. L., & Berns, J. S. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.81 · Cited by 32
HMGB1 promotes differentiation syndrome by inducing hyperinflammation via MEK/ERK signaling in acute promyelocytic leukemia cells
Tang, L., Chai, W., Ye, F., Yu, Y. P., Cao, L., Yang, M., Xie, M., & Yang, L. (2017) · Oncotarget · doi:10.18632/oncotarget.15432 · Cited by 31
Pathophysiology, clinical features and radiological findings of differentiation syndrome/all-trans-retinoic acid syndrome
Cardinale, L. (2014) · World Journal of Radiology · doi:10.4329/wjr.v6.i8.583 · Cited by 30
Transglutaminase 2 programs differentiating acute promyelocytic leukemia cells in all-trans retinoic acid treatment to inflammatory stage through NF-κB activation
Jambrovics, K., Uray, I. P., Keresztessy, Z., Keillor, J. W., Fésüs, L., & Balajthy, Z. (2018) · Haematologica · doi:10.3324/haematol.2018.192823 · Cited by 30
When Poisons Cure: The Case of Arsenic in Acute Promyelocytic Leukemia
Gurnari, C., Bellis, E. D., Divona, M., Ottone, T., Lavorgna, S., & Voso, M. T. (2019) · Chemotherapy · doi:10.1159/000507805 · Cited by 30
Acute Promyelocytic Leukemia in Children: A Model of Precision Medicine and Chemotherapy-Free Therapy
Gurnari, C., Voso, M. T., Girardi, K., Mastronuzzi, A., & Strocchio, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020642 · Cited by 33
FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation
Woods, A. C., Norsworthy, K. J., Wang, X., Vallejo, J. J., Chow, E. C. Y., Li, R., Sun, J., Charlab, R., Jiang, X., Pazdur, R., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2234 · Cited by 30
A Contemporary Review of Blood Transfusion in Critically Ill Patients
Yadav, S. K., Hussein, G., Liu, B., Vojjala, N., Warsame, M., Labban, M. E., Rauf, I., Hassan, M. S., Zareen, T., Usama, S. M., et al. (2024) · Medicina · doi:10.3390/medicina60081247 · Cited by 37
Prolonged intracellular accumulation of light-inducible nanoparticles in leukemia cells allows their remote activation
Boto, C., Quartin, E., Cai, Y., Martín-Lorenzo, A., Cenador, M. B. G., Pinto, S., Gupta, R., Enver, T., Sánchez-García, I., Hong, D., et al. (2017) · Nature Communications · doi:10.1038/ncomms15204 · Cited by 28
Therapy‐related acute promyelocytic leukemia: observations relating to APL pathogenesis and therapy*
Elliott, M. A., Letendre, L., Tefferi, A., Hogan, W. J., Hook, C. C., Kaufmann, S. H., Pruthi, R. K., Pardanani, A. D., Begna, K. H., Ashrani, A. A., et al. (2011) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2011.01727.x · Cited by 28
DNA vaccination with all-trans retinoic acid treatment induces long-term survival and elicits specific immune responses requiring CD4+ and CD8+ T-cell activation in an acute promyelocytic leukemia mouse model
Furugaki, K., Pokorná, K., Pogam, C. L., Aoki, M., Reboul, M., Bajzik, V., Krief, P., Janin, A., Noguera, M.-E., West, R., et al. (2009) · Blood · doi:10.1182/blood-2007-08-109009 · Cited by 28
Outcomes in Adult Acute Promyelocytic Leukemia: A Decade Experience
Yedla, R. P., Bala, S. C., Pydi, V. R., Kuruva, S. P., Chennamaneni, R., Konatam, M. L., Paul, T. R., & Gundeti, S. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.12.011 · Cited by 27
Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial
Platzbecker, U., Adès, L., Montesinos, P., Ammatuna, E., Fenaux, P., Baldus, C. D., Bernardi, M., Berthon, C., Bocchia, M., Bonmati, C., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00535 · Cited by 28
Self-citation
Predictive factors for all-trans retinoic acid-related differentiation syndrome in patients with acute promyelocytic leukemia
Leblebjian, H., DeAngelo, D. J., Skirvin, J. A., Stone, R. M., Wadleigh, M., Werner, L. L., Neuberg, D. S., Bartel, S. B., & McDonnell, A. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.04.011 · Cited by 26
Progressive hyperleukocytosis is a relevant predictive marker for differentiation syndrome, early death, and subsequent relapse in acute promyelocytic leukemia
Yoon, J., Kim, H., Min, G. J., Park, S., Jeon, Y., Lee, S., Cho, B., Eom, K., Kim, Y., Lee, S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-47937-4 · Cited by 26
Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy
on behalf of the PETHEMA, H., Martínez‐Cuadrón, D., Montesinos, P., Vellenga, E., Bernal, T., Salamero, O., Hołowiecka, A., Brunet, S., Gil, C., Benavente, C., et al. (2017) · Leukemia · doi:10.1038/leu.2017.178 · Cited by 25
Self-citation
Acute Promyelocytic Leukemia: A Summary.
Ryan, M. (2018) · Europe PMC (PubMed Central) · Cited by 25

Authors: Montesinos, P., Bergua, J. M., Vellenga, E., Rayón, C., Parody, R., de la Serna, J., León, A., Esteve, J., Milone, G., Debén, G., Rivas, C., González, M., Tormo, M., Díaz-Mediavilla, J., González, J. D., Negri, S., Amutio, E., Brunet, S., Lowenberg, B., & Sanz, M. A.
Affiliations: Universitat Autònoma de Barcelona (ES)
Hospital San Pedro de Alcántara (ES)
University Medical Center Groningen (NL)
Hospital Universitario Central de Asturias (ES)
Hospital Universitario Virgen del Rocío (ES)
Hospital 12 de Octubre, Madrid, Spain;
Hospital General, Jerez de la Frontera, Spain;
Hospital Clínic de Barcelona (ES)
Fundaleu, Buenos Aires, Argentina;
Hospital Juan Canalejo, La Coruña, Spain;
Hospital General Universitario de Alicante Doctor Balmis (ES)
Hospital Universitario, Salamanca, Spain;
Hospital Clínico Universitario de Valencia (ES)
Hospital Clínico San Carlos, Madrid, Spain;
Hospital Insular, Las Palmas, Spain;
Hospital Carlos Haya, Málaga, Spain;
Hospital de Cruces (ES)
Hospital de Sant Pau (ES)
Erasmus University Medical Center, Rotterdam, The Netherlands
Hospital Universitario La Fe, Valencia, Spain;
ORCID: Montesinos, Pau
Bergua, Juan M.
Vellenga, Edo
Esteve, Jordi
González, Marcos
Tormo, Mar
Negri, Silvia
Brunet, Salut
Venue: Blood
Publisher: American Society of Hematology
Published: 2009-01-22
Volume: 113
Issue: 4
Pages: 775-783
ISSN: 0006-4971 (ISSN-L)
1528-0020
DOI: 10.1182/blood-2008-07-168617
OpenAlex: W1982745688
Cited by: 362
References: 42
Citations by year: 2026: 19 · 2025: 22 · 2024: 31 · 2023: 23 · 2022: 21 · 2021: 33 · 2020: 33 · 2019: 22 · 2018: 23 · 2017: 19 · 2016: 16 · 2015: 15 · 2014: 17 · 2013: 8 · 2012: 11
FWCI: 6.58
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Blood (publishedVersion)
PubMed (publishedVersion)
EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
Keywords: differentiation syndrome, acute promyelocytic leukemia, all-trans retinoic acid, idarubicin, anthracycline chemotherapy, prognostic factors, mortality, relapse-free survival, dexamethasone prophylaxis, serum creatinine, white blood cell count
MeSH terms: Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Prognosis, Recurrence, Risk Factors, Syndrome, Time Factors, Tretinoin, Leukemia, Promyelocytic, Acute, Disease-Free Survival, Anthracyclines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks